首页
肿瘤患者与健康对照人群半胱氨酸蛋白酶抑制剂C水平的比较研究
The Levels of Serum Cystatin C in Patients with Tumors and Healthy Controls
-
摘要: 目的 探讨血清半胱氨酸蛋白酶抑制剂C（cystatin C）浓度水平与肿瘤的关系。 方法 颗粒增强免疫比浊法测定273例实体恶性肿瘤患者（肿瘤组）和185例健康体检者（对照组）的血清cystatin C浓度，比较两组血清cystatin C浓度水平的差异并分析其影响因素。 结果 肿瘤组、对照组cystatin C水平差异无统计学意义（P=0.075）；但去除混杂因素年龄的影响后两者差异有统计学意义（P<0.01）；且多元回归分析显示cystatin C水平对照组比肿瘤组高、男性比女性高，且随年龄增长、肾小球滤过率（eGFR）水平下降而升高。 结论 Cystatin C可能在肿瘤的发生发展中起到一定作用。
-
关键词:
- 肿瘤 /
- 半胱氨酸蛋白酶抑制剂C
Abstract: Objective To determine the association between serum cystatin C and tumors. Methods Serum samples were obtained from 273 patients with tumors and 185 healthy volunteers. Serum cystatin C was determined by particle-enhanced turbidimetric immunoassay (PETIA). Student t-test, covariance analysis and multiple linear regressions were performed to examine the differences in the levels of cystatin C between the two groups. Results The student t-test did not show significant statistical differences in the serum cystatin C levels between the two groups (P=0.075). However, such differences became statistically significant (P<0.01) after adjustment of age. The multiple liner regression demonstrated that healthy volunteers and men had higher levels of cystatin C than those with tumors and women. Cystatin C also increased with age and decreases with estimating glomerular filtration rate. Conclusion Cystatin C may be associated with the genesis and development of tumors.-
Keywords:
- Tumor /
- Cystatin C
-
-
[1] 王 蕾, 陈凌燕, 高 锋.半胱氨酸蛋白酶抑制剂C在肿瘤研究中的进展. 检验医学,2008;23(2):199-201. [2] Levey AS, Greene T, Kusek JW, et al. A simplified equation to predict glomerular filtration rate from serum creatinine[Abstract]. J Am Soc Nephrol,2000;11:A0828.
[3] Shlipak MG, Praught ML, Sarnak MJ. Update on cystatin C:new insights into the importance of mild kidney dysfunction. Curr Opin Nephrol Hypertens,2006;15(3):270-275.
[4] Kopitz C, Anton M, Gansbacher B,et al. Reduction of experimental human fibrosarcoma lung metastasis in mice by adenovirus-mediated cystatin C overexpression in the host. Cancer Res,2005;65(19):8608-8612.
[5] Sokol JP, Schiemann WP.Cystatin C antagonizes transforming growth factor beta signaling in normal and cancer cells.Mol Cancer Res,2004;2(3):183-1955.
[6] Strojan P, Oblak I,Svetic B, et al.Cysteine proteinase inhibitor cystatin C in squamous cell tumor of the head and neck:relation to prognosis.Br J Cancer,2004;90(10):1961-1968.
[7] Yano M, Hirai K, Naito Z, et al.Expression of cathepsin B and cystatin C in human breast cancer.Surg Today,2001;31(5):385-389.
[8] 孟令华, 刘 巍, 宋丽楠.BCSGI、C-erbB-2、VEGF表达与乳腺癌临床病理因素相关性研究.中华乳腺病杂志 (电子版),2007;1(4):82-86. [9] Zsebik B, Symonowicz K, Saleh Y, et al.Photodynamic therapy combined with a cysteine proteinase inhibitor synergistically decrease VEGF production and promote tumour necrosis in a rat mammary carcinoma. Cell Prolif,2007;40(1):38-49.
[10] 刘 晔, 郭 晔, 吴慧娟等. 凋亡诱导因子介导顺铂诱导的肾小管上皮细胞凋亡. 中华肿瘤杂志,2010;32(3):173-178. [11] 王明婕, 刘彦信, 张锦春等. 8-氯腺苷增强肿瘤细胞对TRAIL杀伤作用敏感性的研究. 中华肿瘤杂志,2005;27(10):586-590. [12] Maillard N, Mariat C, Bonneau C, et al. Cystatin C-based equations in renal transplantation:moving toward a better glomerular filtration rate prediction? Transplantation,2008;85(12):1855-1858.
[13] 方一卿, 马 骏, 沈汉超等.血清胱抑素 C评价慢性肾脏病患者早期肾损害的临床研究. 中国中西医结合肾病,2007;8(3):145-148. [14] Hoek FJ, Korevaar JC, Dekker FW, et al. Estimation of residual glomerular filtration rate in dialysis patients from the plasma cystatin C level. Nephrol Dial Transplant,2007;22(6):1633-1638.
[15] Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function:a meta-analysis. American Journal of Kidney Diseases,2002;40(2):221-226.
[16] Groesbeck D, Kottgen A, Parekh R, et al. Age, gender, and race effects on cystatin C levels in US adolescents. Clin J Am Soc Nephrol,2008;3(6):1777-1785.
[17] 杜晓英. cystatin C在肾移植领域的研究进展. 国际移植与血液净化,2006;4(2):28-31.
计量
- 文章访问数: 3129
- HTML全文浏览量: 159
- PDF下载量: 59
下载:
